Literature DB >> 16256230

Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer.

Olivier Chapet1, Feng-Ming Kong, Julia S Lee, James A Hayman, Randall K Ten Haken.   

Abstract

PURPOSE: To evaluate the ability of a well-known normal tissue complication probability (NTCP) model to predict radiation esophagitis by determining updated model parameters and then comparing these results with the predictive value of other dosimetric parameters.
MATERIAL AND METHODS: Clinical and dosimetric data regarding esophagitis were analyzed in 101 inoperable/unresectable non-small-cell lung cancer patients treated by external beam irradiation. Grade 2 or higher esophagitis counted as events. Parameters (TD50, n, and m) of the Lyman normal tissue complication probability (NTCP) model were determined using maximum likelihood analysis, and compared to other dose/volume threshold values including: percentage of esophagus receiving > 40 Gy (V40) to > 75 Gy (V75), and maximum esophageal doses.
RESULTS: Sixteen patients developed grade 2-3 acute esophagitis (no G4 or 5). The maximum likelihood analysis produced new Lyman model parameters of: TD50 = 51 Gy, n = 0.44 and m = 0.32. The mean NTCP value is significantly lower (P < 0.001) in the group of patients without esophagitis (13.5%) than with esophagitis (27.2%). The rates of esophagitis are 2.5, 7, 9 and 13.4%, respectively, when the NTCP values are <10%, <15%, <20% and <25%. A significant association is found between esophagitis and dose/volume parameters V40 (P = 0.001) to V70 (P = 0.024).
CONCLUSIONS: New values of TD50, n and m offer a good description of the esophagitis distribution in our population. Compared to the use of this model with previously published parameters (associated with late toxicity) predictions of the model for acute esophagitis using the new parameters would indicate that, for a population of patients, the distribution of events as a function of uniform dose would occur with a lower mean uniform dose value (smaller TD50), over a wider range of uniform doses (larger m), while also exhibiting a bigger volume effect (larger n). These new parameter values are supported in essence by the correlations found for the dose/volume threshold parameters.

Entities:  

Mesh:

Year:  2005        PMID: 16256230     DOI: 10.1016/j.radonc.2005.10.001

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  29 in total

Review 1.  Radiation dose-volume effects in the esophagus.

Authors:  Maria Werner-Wasik; Ellen Yorke; Joseph Deasy; Jiho Nam; Lawrence B Marks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

2.  Dosimetric comparison of free-breathing and deep inspiration breath-hold radiotherapy for lung cancer.

Authors:  V Marchand; S Zefkili; J Desrousseaux; L Simon; C Dauphinot; P Giraud
Journal:  Strahlenther Onkol       Date:  2012-05-17       Impact factor: 3.621

3.  Adaptive radiotherapy in lung cancer: dosimetric benefits and clinical outcome.

Authors:  T Kataria; D Gupta; S S Bisht; N Karthikeyan; S Goyal; L Pushpan; A Abhishek; H B Govardhan; V Kumar; K Sharma; S Jain; T Basu; A Srivastava
Journal:  Br J Radiol       Date:  2014-03-17       Impact factor: 3.039

4.  Radiobiological analysis of stereotactic body radiation therapy for an evidence-based planning target volume of the lung using multiphase CT images obtained with a pneumatic abdominal compression apparatus: a case study.

Authors:  Arun Chairmadurai; Harish Chandra Goel; Sandeep Kumar Jain; Pawan Kumar
Journal:  Radiol Phys Technol       Date:  2017-11-11

5.  Digestive toxicities after palliative three-dimensional conformal radiation therapy (3D-CRT) for cervico-thoracic spinal metastases.

Authors:  Guillaume Peyraga; Delphine Caron; Thibaut Lizee; Yann Metayer; Anne-Lise Septans; Yoann Pointreau; Fabrice Denis; Gerard Ganem; Cedrik Lafond; Sophie Roche; Olivier Dupuis
Journal:  Support Care Cancer       Date:  2017-12-23       Impact factor: 3.603

Review 6.  Esophagitis, treatment-related toxicity in non-small cell lung cancer.

Authors:  Voichita Bar-Ad; Nitin Ohri; Maria Werner-Wasik
Journal:  Rev Recent Clin Trials       Date:  2012-02

7.  Modeling the risk of radiation-induced acute esophagitis for combined Washington University and RTOG trial 93-11 lung cancer patients.

Authors:  Ellen X Huang; Jeffrey D Bradley; Issam El Naqa; Andrew J Hope; Patricia E Lindsay; Walter R Bosch; John W Matthews; William T Sause; Mary V Graham; Joseph O Deasy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-06-14       Impact factor: 7.038

8.  Radiation-induced oesophagitis in lung cancer patients. Is susceptibility for neutropenia a risk factor?

Authors:  D De Ruysscher; J Van Meerbeeck; K Vandecasteele; C Oberije; M Pijls; A M C Dingemans; B Reymen; A van Baardwijk; R Wanders; G Lammering; P Lambin; W De Neve
Journal:  Strahlenther Onkol       Date:  2012-04-29       Impact factor: 3.621

9.  Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated.

Authors:  Soo-Yeon Park; Young Mee Kim; Hongryull Pyo
Journal:  Mol Cancer       Date:  2010-08-23       Impact factor: 27.401

10.  Perspectives on the model-based approach to proton therapy trials: A retrospective study of a lung cancer randomized trial.

Authors:  Aimee L McNamara; David C Hall; Nadya Shusharina; Amy Liu; Xiong Wei; Ali Ajdari; Radhe Mohan; Zhongxing Liao; Harald Paganetti
Journal:  Radiother Oncol       Date:  2020-03-27       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.